These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 15254792

  • 1. Comparison of alpha-dihydroergocryptine and levodopa monotherapy in Parkinson's disease: assessment of changes in DAT binding with [123I]IPT SPECT.
    Pöpperl G, Tatsch K, Ruzicka E, Storch A, Gasser T, Schwarz J.
    J Neural Transm (Vienna); 2004 Aug; 111(8):1041-52. PubMed ID: 15254792
    [Abstract] [Full Text] [Related]

  • 2. Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years.
    Chouker M, Tatsch K, Linke R, Pogarell O, Hahn K, Schwarz J.
    Nucl Med Commun; 2001 Jun; 22(6):721-5. PubMed ID: 11403185
    [Abstract] [Full Text] [Related]

  • 3. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
    Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, Wolters EC, van Royen EA.
    J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
    [Abstract] [Full Text] [Related]

  • 4. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
    Parkinson Study Group.
    JAMA; 2002 Apr 03; 287(13):1653-61. PubMed ID: 11926889
    [Abstract] [Full Text] [Related]

  • 5. Levodopa and the progression of Parkinson's disease.
    Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K, Parkinson Study Group.
    N Engl J Med; 2004 Dec 09; 351(24):2498-508. PubMed ID: 15590952
    [Abstract] [Full Text] [Related]

  • 6. Do dopamine agonists or levodopa modify Parkinson's disease progression?
    Marek K, Jennings D, Seibyl J.
    Eur J Neurol; 2002 Nov 09; 9 Suppl 3():15-22. PubMed ID: 12464117
    [Abstract] [Full Text] [Related]

  • 7. Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease.
    Scherfler C, Seppi K, Donnemiller E, Goebel G, Brenneis C, Virgolini I, Wenning GK, Poewe W.
    Brain; 2005 Jul 09; 128(Pt 7):1605-12. PubMed ID: 15817519
    [Abstract] [Full Text] [Related]

  • 8. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction.
    Sakakibara R, Shinotoh H, Uchiyama T, Yoshiyama M, Hattori T, Yamanishi T.
    J Neurol Sci; 2001 Jun 15; 187(1-2):55-9. PubMed ID: 11440745
    [Abstract] [Full Text] [Related]

  • 9. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group.
    JAMA; 2000 Oct 18; 284(15):1931-8. PubMed ID: 11035889
    [Abstract] [Full Text] [Related]

  • 10. Striatal dopamine transporter binding assessed by [I-123]IPT and single photon emission computed tomography in patients with early Parkinson's disease: implications for a preclinical diagnosis.
    Schwarz J, Linke R, Kerner M, Mozley PD, Trenkwalder C, Gasser T, Tatsch K.
    Arch Neurol; 2000 Feb 18; 57(2):205-8. PubMed ID: 10681078
    [Abstract] [Full Text] [Related]

  • 11. Dopamine transporter gene polymorphism, spect imaging, and levodopa response in patients with Parkinson disease.
    Contin M, Martinelli P, Mochi M, Albani F, Riva R, Scaglione C, Dondi M, Fanti S, Pettinato C, Baruzzi A.
    Clin Neuropharmacol; 2004 Feb 18; 27(3):111-5. PubMed ID: 15190232
    [Abstract] [Full Text] [Related]

  • 12. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison.
    Walker Z, Costa DC, Walker RW, Lee L, Livingston G, Jaros E, Perry R, McKeith I, Katona CL.
    Neurology; 2004 May 11; 62(9):1568-72. PubMed ID: 15136683
    [Abstract] [Full Text] [Related]

  • 13. Reduced striatal dopaminergic innervation shown by IPT and SPECT in patients under neuroleptic treatment: need for levodopa therapy?
    Schwarz J, Scherer J, Trenkwalder C, Mozley PD, Tatsch K.
    Psychiatry Res; 1998 Jul 15; 83(1):23-8. PubMed ID: 9754702
    [Abstract] [Full Text] [Related]

  • 14. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism.
    Lorberboym M, Djaldetti R, Melamed E, Sadeh M, Lampl Y.
    J Nucl Med; 2004 Oct 15; 45(10):1688-93. PubMed ID: 15471834
    [Abstract] [Full Text] [Related]

  • 15. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT.
    Booij J, Hemelaar TG, Speelman JD, de Bruin K, Janssen AG, van Royen EA.
    J Nucl Med; 1999 May 15; 40(5):753-61. PubMed ID: 10319746
    [Abstract] [Full Text] [Related]

  • 16. Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson's disease: analysis with [(123)I]IPT single photon emission computed tomography.
    Im JH, Chung SJ, Kim JS, Lee MC.
    J Neurol Sci; 2006 May 15; 244(1-2):103-9. PubMed ID: 16473371
    [Abstract] [Full Text] [Related]

  • 17. Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography.
    Tatsch K, Schwarz J, Mozley PD, Linke R, Pogarell O, Oertel WH, Fieber RS, Hahn K, Kung HF.
    Eur J Nucl Med; 1997 Apr 15; 24(4):415-21. PubMed ID: 9096093
    [Abstract] [Full Text] [Related]

  • 18. Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson's disease.
    Andringa G, Drukarch B, Bol JG, de Bruin K, Sorman K, Habraken JB, Booij J.
    Neuroimage; 2005 Jul 15; 26(4):1150-8. PubMed ID: 15908232
    [Abstract] [Full Text] [Related]

  • 19. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, van Royen EA, Stoof JC, Wolters EC.
    J Nucl Med; 1998 Jul 15; 39(7):1143-8. PubMed ID: 9669384
    [Abstract] [Full Text] [Related]

  • 20. Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: a 123I-FP-CIT SPECT study.
    Roselli F, Pisciotta NM, Perneczky R, Pennelli M, Aniello MS, De Caro MF, Ferrannini E, Tartaglione B, Defazio G, Rubini G, Livrea P.
    Mov Disord; 2009 Oct 30; 24(14):2097-103. PubMed ID: 19705471
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.